
Michael Kleinrock from IQVIA joined Drug Topics to discuss his company’s recently released report, Understanding the Use of Medicines in the US 2025.

Michael Kleinrock from IQVIA joined Drug Topics to discuss his company’s recently released report, Understanding the Use of Medicines in the US 2025.

Researchers conducted a narrative review of the insulins available for diabetes management and which pharmacological options are best in the perioperative period and within clinical care.

Researchers explored the global disease burden of allergic-related skin diseases from 1990 to 2021 and projected future disease trends.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.

Pharmacists can transform from only being prescription dispensers to health care hubs that offer comprehensive patient care and generate innovative revenue streams.

Researchers conducted a content analysis to identify pharmacy benefit manager legislation supported by the NCPA and assessed whether or not it would benefit rural pharmacies and patients.

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Researchers explored a variety of medicinal plants used for skin-related conditions and assessed their efficacy in treating UV-induced skin damage.

The key theme, regardless of strategy, is being an engaging member of the community and stepping outside of the counter.

Women who received mindfulness-based interventions experienced improved sleep quality and reduced anxiety, depressive symptoms, and stress.

Researchers conducted a survey assessing pharmacy students’ perceptions of pharmacist burnout and how that may impact their future career paths.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the importance of insulin delivery and the common barriers pharmacists face in managing patients’ regimens.

Researchers investigated the current treatment strategies for atopic dermatitis and how they related to ideas of corticophobia among providers.

CPESN USA announces the recipients of its 2025 CPESN Most Engaged Pharmacy Awards and recognizes 32 pharmacies from across America.

Patients with a single cardiometabolic disease have an approximately 48% greater risk of developing all-cause dementia than those without a cardiometabolic disease.

Researchers explored the effectiveness of telephonic insulin titration by a clinical pharmacist compared with in-office titration among patients in a medical residency clinic.

Brett Barker, PharmD, state representative in Iowa’s 51st District, joined Drug Topics to discuss significant implications and common misconceptions regarding Iowa’s new PBM bill.

Efsitora demonstrates noninferior reductions in hemoglobin A1c and similar rates in patients with an A1c level less than 7% compared with common daily insulin.

The therapy is now the first and only oral on-demand treatment option for the condition.

Researchers determined the impact COVID-19 interventions had on Danish children’s incidence of RSV, influenza, and invasive pneumococcal disease.

This year’s conference is taking place from July 10 to 13 in Nashville, Tennessee.

Investigators also report that sodium-glucose cotransporter 2 inhibitors are not associated with thrombotic risk.

Health care professionals emphasize patient education and reliable information in the evolving vaccine recommendation landscape.

Kevin W. Cleveland, PharmD, urges evidence-based approaches to immunizations in an era of uncertainty.

Patients who used the Bigfoot Unity Diabetes Management System had glycemic control and reduced diabetes distress.

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, discusses the impact of shifting guidance on vaccination strategies.

As concerns mount over potential shifts in vaccine recommendations, Deanna Tran, PharmD, BCACP, FAPhA, advocates for rigorous data assessment and patient-centered communication strategies.

In part 3 of our interview with Walgreens Chief Pharmacy Officer Rick Gates, he explores the future of pharmacy practices and how modern use of technologies like AI are becoming commonplace.


Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.